| Literature DB >> 29662893 |
Shanshan Zhu1, Jie Gao1, Tao Ding1, Junhua Xu1, Min Wu1.
Abstract
Aims/Introduction. Evidences have shown that the deteriorated procession of disease is not a smooth change with time and conditions, in which a critical transition point denoted as predisease state drives the state from normal to disease. Considering individual differences, this paper provides a sample-specific method that constructs an index with individual-specific dynamical network biomarkers (DNB) which are defined as early warning index (EWI) for detecting predisease state of individual sample. Based on microarray data of influenza A disease, 144 genes are selected as DNB and the 7th time period is defined as predisease state. In addition, according to functional analysis of the discovered DNB, it is relevant with experience data, which can illustrate the effectiveness of our sample-specific method.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29662893 PMCID: PMC5831949 DOI: 10.1155/2018/6807059
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Three parts of biological progression of disease of a living organism. (a) The disease progression consists of three states including normal state, predisease state, and disease state, respectively. As shown in the picture, the process from normal to predisease state is reversible, whereas the process from predisease to disease state is irreversible. (b) The static variation displays the development progression of disease and the average value of molecule concentrations (e.g., gene or protein expression) at each state. (c) The dynamic variation shows the development progression of disease and the dynamic value of molecule concentrations (e.g., gene or protein expression) at each state.
Figure 2The early warning index of influenza disease. In all the figures, the abscissa represents the time point t. (a) The average coefficient variation (CV) of genes expression in DNB at 10 time points. (b) The average difference in absolute value between genes expression inside DNB and any other outside DNB (ODIF) at 10 time points. (c) The average difference (DIF) in absolute value of genes expression in DNB at 10 time points. (d) The early warning index (EWI) of the case set of high-throughput experimental data for influenza A disease.
Functional enrichment of GO for part of genes of identified DNB.
| GO term | Description | DNB |
| Corrected |
|---|---|---|---|---|
| GO:0007155 | Cell adhesion | ARVCF, COL19A1, OLR1, CD300A, PCDHA10, CX3CL1, OMG, SIGLEC9 | 0.03844 | 0.85044 |
| GO:0045766 | Positive regulation of angiogenesis | ADM2, NOS3, CX3CL1, ALOX12 | 0.04448 | 0.86098 |
| GO:0005886 | Plasma membrane | SCN3B, GRIK2, TGFB3, SLC7A9, DMPK, APOA1,… | 9.55 | 1.56 |
| GO:0005615 | Extracellular space | LPL, CRISP3, LUM, AFM, IFNA10, TGFB3, CX3CL, BMP15, APOA1, APOL1, IL18BP,… | 1.23 | 0.00400 |
| GO:0005102 | Receptor binding | HAO1, LPL, TENM2, HAO2, CX3CL1, LTB | 0.03689 | 0.97736 |
| GO:0010181 | FMN binding | HAO1, HAO2, NOS3 | 0.00418 | 0.67592 |
Functional enrichment of KEGG pathways for part of genes of identified DNB.
| Pathway term | DNB |
| |
|---|---|---|---|
| hsa04060 | Cytokine-cytokine receptor interaction | CXCR6; IFNA10; IL21R; TGFB3; LTB; EDA2R; CX3CL1; IL13RA1; IL3RA | 3.24 |
| hsa03320 | PPAR signaling pathway | LPL; APOA1; OLR1; APOC3 | 1.45 |
Figure 3Key biological pathways with DNB genes in cytokine-cytokine receptor interaction and PPAR signaling pathway.